Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
In the company’s third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations ... within our expectations,” the company said. Lilly’s stock has tumbled ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...
The stock has also outperformed the sector as well as the S&P 500, as seen in the chart below. The stupendous success of Mounjaro and Zepbound has made Lilly the largest drugmaker with a market ...
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed ... the company said. Lilly's stock has tumbled 21.3% over the past three months ...